3rd Quarter - Report

AMERICAN CLINICAL LABORATORY ASSN for AMERICAN CLINICAL LABORATORY ASSN

Period 3rd Quarter 2018 Filed Oct 19, 2018 Signed by Thomas Bryant Sparkman

Official filing

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm
AMERICAN CLINICAL LABORATORY ASSN
Client
AMERICAN CLINICAL LABORATORY ASSN
Income
—
Expenses
$154,700
Expense method
C: businesses, Internal Revenue Code section 162(e)

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
3rd Quarter - Report (this page) Oct 19, 2018 $154,700 Replaced
3rd Quarter - Amendment Oct 26, 2018 $461,462 Yes

What was lobbied

7 issue areas, each in the filer's own words, with who lobbied on it and where.

Alcohol and Drug Abuse ALC

H.R.6 SUPPORT for Patients and Communities Act; role of clinical laboratory services in treating, detecting and preventing opioid and chemical substance abuse, addiction, and diversion.

LobbyistCovered position, as disclosed
THOMAS B SPARKMAN —

Contacted: Office of Management & Budget (OMB); White House Office; Centers For Disease Control & Prevention (CDC); Food & Drug Administration (FDA); SENATE; Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); Defense, Dept of (DOD); HOUSE OF REPRESENTATIVES

Bills named: H.R. 6 (115th)

Disaster Planning/Emergencies DIS

commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 (S 2852/HR 6378)

LobbyistCovered position, as disclosed
DAVID COOLING —
THOMAS B SPARKMAN —

Contacted: Office of Management & Budget (OMB); White House Office; SENATE; Defense, Dept of (DOD); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); Centers For Disease Control & Prevention (CDC); Health & Human Services, Dept of (HHS)

Bills named: H.R. 6378 (115th)

Law Enforcement/Crime/Criminal Justice LAW

H.R.6 SUPPORT for Patients and Communities Act; role of clinical laboratory services in treating, detecting and preventing opioid and chemical substance abuse, addiction, and diversion; application of anti-kickback laws to clinical laboratories

LobbyistCovered position, as disclosed
THOMAS B SPARKMAN —

Contacted: HOUSE OF REPRESENTATIVES; Office of Management & Budget (OMB); White House Office; Health & Human Services, Dept of (HHS); Centers For Disease Control & Prevention (CDC); Defense, Dept of (DOD); Food & Drug Administration (FDA); SENATE; Centers For Medicare and Medicaid Services (CMS)

Bills named: H.R. 6 (115th)

Health Issues HCR

regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 (S 2852/HR 6378); Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018 and FY2019; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services; P.L. 115-245 Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (H.R. 6157); H.R.6 SUPPORT for Patients and Communities Act; role of clinical laboratory services in treating, detecting and preventing opioid and chemical substance abuse, addiction, and diversion.

LobbyistCovered position, as disclosed
DAVID COOLING —
THOMAS B SPARKMAN —

Contacted: SENATE; Centers For Medicare and Medicaid Services (CMS); White House Office; Defense, Dept of (DOD); Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Office of Management & Budget (OMB); Centers For Disease Control & Prevention (CDC)

Bills named: H.R. 6378 (115th), H.R. 1625 (115th), H.R. 6157 (115th), H.R. 6 (115th)

Medicare/Medicaid MMM

reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services

LobbyistCovered position, as disclosed
DAVID COOLING —
THOMAS B SPARKMAN —

Contacted: SENATE; Food & Drug Administration (FDA); Defense, Dept of (DOD); Health & Human Services, Dept of (HHS); White House Office; Centers For Medicare and Medicaid Services (CMS); Centers For Disease Control & Prevention (CDC); HOUSE OF REPRESENTATIVES; Office of Management & Budget (OMB)

Bills named: H.R. 1625 (115th)

Budget/Appropriations BUD

regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018 and FY2019; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services; P.L. 115-245 Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (H.R. 6157)

LobbyistCovered position, as disclosed
DAVID COOLING —
THOMAS B SPARKMAN —

Contacted: HOUSE OF REPRESENTATIVES; Centers For Disease Control & Prevention (CDC); Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); White House Office; Defense, Dept of (DOD); SENATE; Office of Management & Budget (OMB); Centers For Medicare and Medicaid Services (CMS)

Bills named: H.R. 6157 (115th), H.R. 1625 (115th)

Medical/Disease Research/Clinical Labs MED

regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 (S 2852/HR 6378); Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018 and FY2019; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services; P.L. 115-245 Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (H.R. 6157); H.R.6 SUPPORT for Patients and Communities Act; role of clinical laboratory services in treating, detecting and preventing opioid and chemical substance abuse, addiction, and diversion.

LobbyistCovered position, as disclosed
DAVID COOLING —
THOMAS B SPARKMAN —

Contacted: Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Office of Management & Budget (OMB); Centers For Medicare and Medicaid Services (CMS); White House Office; Centers For Disease Control & Prevention (CDC); Food & Drug Administration (FDA); SENATE; Defense, Dept of (DOD)

Bills named: H.R. 6 (115th), H.R. 1625 (115th), H.R. 6157 (115th), H.R. 6378 (115th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.